Technology
Health
Biotechnology

Immuron

$3.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.55 (-15.28%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Immuron and other stocks, options, ETFs, and crypto commission-free!

About IMRN

Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. Read More The Research and Development segment involves the R&D projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers company activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.

Employees
Headquarters
Carlton, Victoria (VIC)
Founded
1994
Market Cap
10.92M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.18M
High Today
$3.57
Low Today
$3.11
Open Price
$3.57
Volume
77.03K
52 Week High
$14.29
52 Week Low
$2.38

Collections

Technology
Health
Biotechnology
Research And Development
2013 IPO

IMRN News

BenzingaJul 16

Why Is Immuron Stock Moving?

286

IMRN Earnings

Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual

More IMRN News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.